Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
Interventions: DRUG: Carboplatin|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab
Sponsor: Northwestern University
Collaborators: Merck Sharp & Dohme LLC|National Cancer Institute (NCI)